By Tony Winterburn • 30 June 2020 • 8:24
AN unspecified number of people will have the vaccine, as part of a trial by Hyderabad-based firm Bharat Biotech, tests in animals suggest the vaccine is safe and triggers an effective immune response.
The trials are among many across the world – there are around 120 vaccine programmes underway, in total there are half a dozen Indian firms developing vaccines. This is the first India-made vaccine and developed from a strain of the virus that was isolated locally and weakened under laboratory conditions.
The trials are set to start across the country in July. COVAXIN has been developed by Hyderabad-based Bharat Biotech, in association with ICMR (Indian Council for Medical Research). It is an inactivated vaccine which created from a strain of the infectious SARS-CoV-2 virus and has shown promise in preclinical studies, demonstrating extensive safety and effective immune responses.
Reportedly, similar efforts are being mounted across the globe, with a number of different drugs in different stages of the trial. Last week, the World Health Organisation (WHO) had said that AstraZeneca’s vaccine was probably the leading candidate.
The Britain-based firm has already begun large-scale, mid-stage human trials of the drug developed by researchers at the University of Oxford.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you donâ€™t already have one. Review our
Share your story with us by emailing email@example.com, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
Download our media pack in either English or Spanish.